We have studied the effects of i.v. bolus doses of magnesium sulphate (MgSO4) 60, 90 and 120 mg kg 91 on haemodynamic state, the coronary circulation and myocardial metabolism in nine dogs anaesthetized with pentobarbitone and fentanyl. MgSO4 produced dose-dependent decreases in arterial pressure, heart rate, left ventricular dP/dtmax and left ventricular minute work index (LVMWI) and an increase in the time constant of left ventricular isovolumic relaxation. Stroke volume increased, systemic vascular resistance decreased and cardiac output did not change significantly. MgSO4 produced decreases in coronary perfusion pressure, coronary vascular resistance and myocardial oxygen consumption MV that is an index of cardiac efficiency, did not change significantly. This study indicated that the depressant effect of MgSO4 on cardiac function was offset by lowering of peripheral vascular resistance, so that cardiac pump function remained effective, and the almost constant coronary sinus blood flow resulted from the decrease in coronary vascular resistance even at higher doses. (Br.
on haemodynamic state, the coronary circulation and myocardial metabolism in nine dogs anaesthetized with pentobarbitone and fentanyl. MgSO4 produced dose-dependent decreases in arterial pressure, heart rate, left ventricular dP/dtmax and left ventricular minute work index (LVMWI) and an increase in the time constant of left ventricular isovolumic relaxation. Stroke volume increased, systemic vascular resistance decreased and cardiac output did not change significantly. MgSO4 produced decreases in coronary perfusion pressure, coronary vascular resistance and myocardial oxygen consumption MV that is an index of cardiac efficiency, did not change significantly. This study indicated that the depressant effect of MgSO4 on cardiac function was offset by lowering of peripheral vascular resistance, so that cardiac pump function remained effective, and the almost constant coronary sinus blood flow resulted from the decrease in coronary vascular resistance even at higher doses. (Br. J. Anaesth. 1997; 79: 363-368). Magnesium sulphate has been used for decades in the management of eclampsia 1 2 and pregnancyinduced hypertension. 3 4 Recent reports on magnesium have emphasized its role in deficiency syndromes, [5] [6] [7] including cardiac arrhythmias. 8 9 10 The therapeutic importance and physiological roles of magnesium have been summarized by Iseri and French, 11 and an extensive review on clinical experiences has been published by James. 12 The evidence for cardiac depression by clinically useful concentrations of hypermagnesaemia is less clear, despite its wide clinical use. Some authors have demonstrated that there is no evidence of myocardial depression at any concentration of serum magnesium, 13 whereas others have reported that a single injection of magnesium sulphate leads to a decrease in cardiac performance.
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14 Although the cardiovascular haemodynamic effects of magnesium sulphate were assessed by some authors in baboons, 13 sheep 15 and humans, 16 there have been few reports on magnesium-induced changes in left ventricular diastolic function. The effects of magnesium sulphate on the coronary circulation and myocardial metabolism have not been studied extensively.
This study was designed to investigate the effects of magnesium sulphate on haemodynamic state, including left ventricular diastolic function, coronary circulation and myocardial metabolism, in open-chest dogs.
Materials and methods
The study was approved by the management committee at Jichi Medical Laboratory of Experimental Medicine, based on the school's Guide for Laboratory Animals, 1993.
Nine mongrel dogs (mean weight 23.5 (range 18-30.5) kg) were anaesthetized with pentobarbitone 30 mg kg 91. After tracheal intubation, the lungs were ventilated with a Harvard pump respirator ( 2 O I F :1.0). Arterial carbon dioxide tension was maintained at 4.8-5.3 kPa, as assessed by continuous measurement of end-tidal carbon dioxide concentration with a calibrated respiratory gas monitor (Model 5250, Ohmeda, Madison, WI.,USA) and repetitive analyses of arterial bloodgas tensions. Temperature was measured with an oesophageal thermistor and maintained at 36-37 ЊC using an external heating pad. Anaesthesia was maintained during surgery with fentanyl 20 g kg 91 h 91 and 0.5-2.0 % sevoflurane in pure oxygen. All animals were paralysed with bolus doses of pancuronium 0.2 mg kg 91 followed by small doses as needed.
Heart rate (HR) was monitored by electrocardiography (ECG, lead II), and systolic, diastolic and mean arterial pressures (SAP, DAP and MAP, respectively) were measured with a micromanometer-tipped catheter (7F 45326, Toyoda, Ltd, Tokyo, Japan) placed via the left femoral artery into the abdominal aorta. A catheter was placed in the abdominal aorta via the right femoral artery for arterial blood sampling. Lactated Ringer's solution was infused at 5-10 ml kg 91 h 91 into the right femoral vein throughout the experiment.
After median sternotomy, an appropriately sized electromagnetic flow transducer (FB-140T, Nihon Kohden, Ltd, Tokyo, Japan) was placed around the root of the ascending aorta and connected to a flowmeter (MFW2100, Nihon Kohden, Ltd, Tokyo, Japan) for measurement of ascending aortic flow and cardiac output (CO). A micro-tip catheter (8F PC380, Millar, Inc.) was inserted through a stab wound in the apex of the left ventricle for measurements of left ventricular pressure (LVP) and left ventricular enddiastolic pressure (LVEDP). The rate of increase of left ventricular pressure (LVdP/dt) was obtained with an analogue differentiating circuit incorporated with an analogue-to-digital converter (Contractility Unit 1323, NEC San-ei, Ltd, Tokyo, Japan) and used as an index of left ventricular contractile function. Coronary sinus blood flow (CSBF) was measured by the retrograde thermodilution technique with a catheter (Thermoflow CCS-7U-90A, Webster Labs., Inc.) inserted into the coronary sinus via the right auricle. 17 Cold normal saline as the indicator was infused at 20 ml min 91 for 20 s with an infusion pump (SW-367, Sage Inst., Inc.) through the catheter for each measurement of CSBF. A pair of piezoelectric crystals (5 MHz, Sonotek Co., San Diego, CA, USA) were inserted into the subendocardium in the anterior and posterior walls of the left ventricle and connected to an amplifier (amplifier Unit 4105, NEC San-ei., Ltd, Tokyo, Japan) for measurement of left ventricular enddiastolic and end-systolic diameters (LVEDD and LVESD). Fractional shortening (FS) was obtained using the following formula and used as an index of left ventricular contractile function: FS: (LVEDD-LVESD)/LVEDDϫ100. All variables were recorded continuously on a polygraph (RECTI-HORIZ-8K23, NEC San-ei, Ltd, Tokyo, Japan).
Arterial and coronary sinus blood was sampled simultaneously to measure pH, PO 2 , PCO 2 , base excess, standard bicarbonate and haemoglobin concentrations (288 Blood Gas System, Ciba Corning), lactate, non-esterified fatty acid (NEFA) and magnesium concentrations. Lactate concentrations were measured using an enzymatic method. Myocardial oxygen consumption Left ventricular pressure (LVP), LVdP/dt, LVEDP and ECG signals were fed to a multichannel photographic oscillograph (Visigraph 5137, NEC San-ei Inst., Ltd, Tokyo, Japan) and recorded at a paper speed of 500 mm s 91 to obtain the time constant of left ventricular isovolumic relaxation (T). T was calculated according to the method of Weiss, Frederiksen and Weisfeldt 18 and used as an index of left ventricular relaxation.
At the end of the surgical procedure, sevoflurane was discontinued and fentanyl was infused at a rate of 20 g kg 91 h
91
. Approximately 30 min was allowed after withdrawal of sevoflurane for stabilization of haemodynamic variables and baseline values were obtained. All dogs were given a 12.3% solution of magnesium sulphate in a bolus dose of 60, 90 and 120 mg kg 91 (0.49, 0.73 and 0.98 ml kg
, respectively) over 10 s at 20-min intervals consecutively. The ratio of osmolarity of magnesium sulphate to that of saline is 3.0 : 1.0. Haemodynamic measurements and blood sampling were performed 1 min before and after each administration of magnesium sulphate.
All values are presented as mean (SEM). Data were analysed statistically using analysis of variance for repeated measurements (ANOVA). Where appropriate, this was followed by the Scheffe F test. A probability of chance occurrence less than 5% (P:0.05) was considered statistically significant. Figure 1 Changes in cardiac output (CO) (!), heart rate (HR) (L) and stroke volume (SV) (I) (mean, SEM) after administration of magnesium sulphate (MgSO4). *P:0.05, **P:0.01 compared with baseline (B). 
Discussion
The major findings of this study were that magnesium sulphate, in a dose-dependent manner, lowered systemic vascular resistance, arterial pressure and heart rate, while cardiac output was well maintained. Cardiac work, derived from both stroke volume and heart rate, and myocardial oxygen consumption, decreased markedly in parallel with systemic vascular resistance. Magnesium sulphate maintained coronary perfusion and cardiac efficiency even at higher doses.
With an unchanged cardiac output, the decrease in arterial pressures must result from a decrease in systemic vascular resistance, which may be caused mainly by the vasodilator effects of magnesium sulphate that have been demonstrated in vitro, 19 20 in intact animals 13 21 and in humans. 15 The cardiovascular effects of magnesium are as follows: (1) inhibition of the normal rhythm or vasomotion (spontaneous mechanical activity) of vascular smooth muscle, (2) depression of the contractile responses to endogenous neurohumoral substances that maintain vascular tone, 22 (3) possibly blockade of sympathetic ganglia 23 and (4) 16 observed that rapid administration of magnesium sulphate produced hypotension but a more gradual administration did not produce hypotension. In our study, magnesium sulphate at bolus doses of 60, 90 and 120 mg kg 91 administered every 20 min produced a dose-dependent decrease in arterial pressure. This decrease in arterial pressure corresponded to increases in serum concentrations of magnesium.
Magnesium sulphate is known to have a negative inotropic action and cause myocardial depression and cardiac arrest in massive doses. 24 In this study, magnesium sulphate produced a dose-dependent decrease in LVdP/dtmax. Although the decrease in LVdP/dtmax can be explained partially by the decrease in heart rate, 26 this indicates that magnesium sulphate exerted a dose-dependent Table 4 Effects of magnesium sulphate (MgSO4) on coronary circulation and myocardial metabolism (mean (SEM)). CPP:Coronary perfusion pressure; CSBF:coronary sinus blood flow; CO:cardiac output; CVR:coronary vascular resistance; negative inotropic action in the whole animal. Left ventricular pump function, however, was well compensated by the increase in stroke volume caused by the lowering of peripheral vascular resistance. In fact, magnesium sulphate 60 and 90 mg kg 91 produced a significant increase in stroke volume despite a marked decrease in LVdP/dtmax. Cardiac output also was maintained well at a high dose of 120 mg kg
91
. The profound decrease in heart rate may be the main effect of magnesium sulphate, with the heart compensating by a Starling effect to increase stroke volume appreciably. This finding is consistent with previous reports. 3 13 27 James, Cork and Dennett 13 15 also demonstrated that magnesium sulphate produced an increase in cardiac output despite significant myocardial depression. These findings and ours suggest that the direct myocardial depressant effect with magnesium may be compensated by decreased afterload, resulting in the maintenance of cardiac function as a pump. No significant change in fractional shortening as an index of left ventricular systolic function during ejection phase could be attributed to the decrease in afterload.
Some authors 16 25 have reported that tachycardia occurred during administration of magnesium sulphate, whereas others 13 have reported that bradycardia was seen. In our study, magnesium sulphate produced a dose-dependent decrease in heart rate and prolongation of PQ and QTc intervals. The degree and rate of increase of blood magnesium concentration may partially explain the different findings observed among these studies. At a low serum concentration of magnesium, hypotension may produce tachycardia through the baroreflex pathway, whereas at a high concentration bradycardia may be brought about by both indirect and direct inhibitory effects of magnesium on the sinoatrial node. As for indirect inhibitory effects, Stanbury 23 found that magnesium induces a short-lived blockade of the sympathetic ganglia and prevents the stimulating effects of potassium and acetylcholine on the superior cervical ganglion in anaesthetized cats. As for direct inhibitory effect, Opthof and colleagues 28 demonstrated that magnesium itself decreased the rate of diastolic depolarization of the pacemaker cells in the sinus node.
In this study, magnesium sulphate did not produce any arrhythmias or conduction disorders at serum concentrations of 6.3 (0.3) to 14.4 (0.7) mg dl
, although it produced a dose-dependent decrease in heart rate and prolongation of PQ, QRS and QTc intervals. This finding is consistent with our earlier study 29 except for QTc interval. The difference of basal anaesthesia may be associated with the different results of QTc interval.
Although the effects of magnesium sulphate on systemic haemodynamic state and myocardial contractility have been described in other studies, 13 15 16 the effect on ventricular diastolic function in vivo or in vitro remains unexplored. In this study, the effect of magnesium sulphate on left ventricular relaxing function was investigated by the time constant of left ventricular isovolumic relaxation (T). The shorter the T value, the better the relaxing function of the left ventricle, and vice versa. 18 Magnesium sulphate produced a dose-dependent increase in T in this study. Therefore, magnesium may depress left ventricular relaxing function. Because T tends to increase with a decrease in heart rate and depressed systolic fibre shortening, 18 the decrease in T observed here appeared to be related not only to decreased left ventricular relaxing function but also to decreased heart rate and depressed systolic fibre shortening.
The effects of magnesium sulphate on the coronary circulation and myocardial metabolism have not been studied extensively. This study demonstrated that magnesium sulphate did not change coronary sinus blood flow remarkably despite a decrease in coronary perfusion pressure. This suggests that magnesium sulphate may have a coronary vasodilating effect. A dose-dependent decrease in 
LVMWI/MV
• did not change significantly. The decrease in LVMWI is thought to be caused mainly by reduction in arterial pressure. Lactate production was not observed throughout this study. Therefore, magnesium sulphate may maintain an appropriate oxygen supply-and-demand relation in the myocardium and may exert no major adverse effects on cardiac function as a pump.
The findings of this study could be related to basal anaesthesia because of an acute open-chest canine preparation under general anaesthesia. Priebe demonstrated an anaesthetic technique comprising pentobarbitone, with fentanyl maintaining a stable, global haemodynamic state over a prolonged period. 30 Cox 31 demonstrated that haemodynamic variables returned to control levels within 15 min after pentobarbitone 30 mg kg 91 i.v. in dogs, although heart rate remained increased from the control value of 85 beat min 91 to 132 beat min 91 even after 60 min. In this study, however, a heart rate of 125 (5) beat min 91 immediately after administration of pentobarbitone decreased to a baseline value of 109 (8) beat min 91 immediately before initiation of measurements.
The osmolarity of magnesium sulphate solutions used could not produce any transient cardiovascular effects because the volumes were small and osmolarity might be lowered by the circulating blood of the dogs.
Magnesium sulphate competes with calcium at the cell membrane and is regarded in many clinical situations as a physiological calcium blocker. This concept may be supported by the facts that magnesium sulphate (1) exerted a mild consistent, dose-dependent hypotensive effect, (2) preserved cardiac pump and coronary sinus blood flow despite a decrease in coronary perfusion pressure, (3) produced negative inotropic effect, (4) decreased myocardial oxygen consumption and (5) did not produce arrhythmia. These effects are thought to be beneficial for patients with ischaemic heart disease.
In future, magnesium will be used more widely in many medical situations, including anaesthetic practice as a physiological calcium blocker.
